MediLink Therapeutics, BioNTech expand partnership with new $1.8bn agreement
MediLink Therapeutics (Suzhou) Co., Ltd., a prominent clinical-stage biotech company, has entered into a significant new strategic collaboration with BioNTech SE, a leader in next-generation immunotherapy. This collaboration involves an exclusive option for BioNTech to secure a global license to utilize MediLink’s innovative TMALIN antibody-drug conjugate (ADC) platform for several novel targets. A Lucrative Collaboration […]